Biogen Inc. - Aug 29, 2022 Form 4 Insider Report for SANGAMO THERAPEUTICS, INC (SGMO)

Role
10%+ Owner
Signature
BIOGEN INC. By: /s/ Michael Dambach, Vice President and Treasurer
Stock symbol
SGMO
Transactions as of
Aug 29, 2022
Transactions value $
-$2,657,240
Form type
4
Date filed
8/31/2022, 07:03 PM
Previous filing
Dec 30, 2021
Next filing
Aug 7, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SGMO Common Stock Sale -$2.13M -400K -1.66% $5.33 23.8M Aug 29, 2022 By Biogen MA Inc. F1, F2
transaction SGMO Common Stock Sale -$527K -100K -0.42% $5.27 23.7M Aug 30, 2022 By Biogen MA Inc. F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.205 to $5.475, inclusive. The reporting person undertakes to provide to Sangamo Therapeutics, Inc., any security holder of Sangamo Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F2 Shares are owned indirectly by Biogen Inc. and directly by its wholly-owned subsidiary Biogen MA Inc.
F3 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.1235 to $5.49, inclusive. The reporting person undertakes to provide to Sangamo Therapeutics, Inc., any security holder of Sangamo Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.